For patients with TNBC and HR+/HER2– breast cancer, a better understanding of their preferences, especially regarding HRQoL when considering perceived treatment-related side effects, may result in improved healthcare decision-making and development of oncological therapies for advanced and metastatic cancer. This evidence concerns the gene ERBB2 and breast cancer.